From design to the clinic: practical guidelines for translating cardiovascular nanomedicine

Iwona Cicha, Cédric Chauvierre, Isabelle Texier, Claudia Cabella, Josbert M. Metselaar, J. Szebeni, László Dézsi, Christoph Alexiou, François Rouzet, Gert Storm, Erik Stroes, Donald Bruce, Neil MacRitchie, Pasquale Maffia, Didier Letourneur

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Cardiovascular diseases (CVD) account for nearly half of all deaths in Europe and almost 30% of global deaths. Despite the improved clinical management, cardiovascular mortality is predicted to rise in the next decades due to the increasing impact of aging, obesity, and diabetes. The goal of emerging cardiovascular nanomedicine is to reduce the burden of CVD using nanoscale medical products and devices. However, the development of novel multicomponent nano-sized products poses multiple technical, ethical, and regulatory challenges, which often obstruct their road to successful approval and use in clinical practice. This review discusses the rational design of nanoparticles, including safety considerations and regulatory issues, and highlights the steps needed to achieve efficient clinical translation of promising nanomedicinal products for cardiovascular applications.

Original languageEnglish
Pages (from-to)1714-1727
Number of pages14
JournalCardiovascular Research
Volume114
Issue number13
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Nanomedicine
Cardiovascular Diseases
Guidelines
Nanoparticles
Obesity
Safety
Equipment and Supplies
Mortality

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Cicha, I., Chauvierre, C., Texier, I., Cabella, C., Metselaar, J. M., Szebeni, J., ... Letourneur, D. (2018). From design to the clinic: practical guidelines for translating cardiovascular nanomedicine. Cardiovascular Research, 114(13), 1714-1727. https://doi.org/10.1093/cvr/cvy219

From design to the clinic : practical guidelines for translating cardiovascular nanomedicine. / Cicha, Iwona; Chauvierre, Cédric; Texier, Isabelle; Cabella, Claudia; Metselaar, Josbert M.; Szebeni, J.; Dézsi, László; Alexiou, Christoph; Rouzet, François; Storm, Gert; Stroes, Erik; Bruce, Donald; MacRitchie, Neil; Maffia, Pasquale; Letourneur, Didier.

In: Cardiovascular Research, Vol. 114, No. 13, 01.11.2018, p. 1714-1727.

Research output: Contribution to journalArticle

Cicha, I, Chauvierre, C, Texier, I, Cabella, C, Metselaar, JM, Szebeni, J, Dézsi, L, Alexiou, C, Rouzet, F, Storm, G, Stroes, E, Bruce, D, MacRitchie, N, Maffia, P & Letourneur, D 2018, 'From design to the clinic: practical guidelines for translating cardiovascular nanomedicine', Cardiovascular Research, vol. 114, no. 13, pp. 1714-1727. https://doi.org/10.1093/cvr/cvy219
Cicha, Iwona ; Chauvierre, Cédric ; Texier, Isabelle ; Cabella, Claudia ; Metselaar, Josbert M. ; Szebeni, J. ; Dézsi, László ; Alexiou, Christoph ; Rouzet, François ; Storm, Gert ; Stroes, Erik ; Bruce, Donald ; MacRitchie, Neil ; Maffia, Pasquale ; Letourneur, Didier. / From design to the clinic : practical guidelines for translating cardiovascular nanomedicine. In: Cardiovascular Research. 2018 ; Vol. 114, No. 13. pp. 1714-1727.
@article{447ab1a8c1a947ae86978321ae1fc292,
title = "From design to the clinic: practical guidelines for translating cardiovascular nanomedicine",
abstract = "Cardiovascular diseases (CVD) account for nearly half of all deaths in Europe and almost 30{\%} of global deaths. Despite the improved clinical management, cardiovascular mortality is predicted to rise in the next decades due to the increasing impact of aging, obesity, and diabetes. The goal of emerging cardiovascular nanomedicine is to reduce the burden of CVD using nanoscale medical products and devices. However, the development of novel multicomponent nano-sized products poses multiple technical, ethical, and regulatory challenges, which often obstruct their road to successful approval and use in clinical practice. This review discusses the rational design of nanoparticles, including safety considerations and regulatory issues, and highlights the steps needed to achieve efficient clinical translation of promising nanomedicinal products for cardiovascular applications.",
author = "Iwona Cicha and C{\'e}dric Chauvierre and Isabelle Texier and Claudia Cabella and Metselaar, {Josbert M.} and J. Szebeni and L{\'a}szl{\'o} D{\'e}zsi and Christoph Alexiou and Fran{\cc}ois Rouzet and Gert Storm and Erik Stroes and Donald Bruce and Neil MacRitchie and Pasquale Maffia and Didier Letourneur",
year = "2018",
month = "11",
day = "1",
doi = "10.1093/cvr/cvy219",
language = "English",
volume = "114",
pages = "1714--1727",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "13",

}

TY - JOUR

T1 - From design to the clinic

T2 - practical guidelines for translating cardiovascular nanomedicine

AU - Cicha, Iwona

AU - Chauvierre, Cédric

AU - Texier, Isabelle

AU - Cabella, Claudia

AU - Metselaar, Josbert M.

AU - Szebeni, J.

AU - Dézsi, László

AU - Alexiou, Christoph

AU - Rouzet, François

AU - Storm, Gert

AU - Stroes, Erik

AU - Bruce, Donald

AU - MacRitchie, Neil

AU - Maffia, Pasquale

AU - Letourneur, Didier

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Cardiovascular diseases (CVD) account for nearly half of all deaths in Europe and almost 30% of global deaths. Despite the improved clinical management, cardiovascular mortality is predicted to rise in the next decades due to the increasing impact of aging, obesity, and diabetes. The goal of emerging cardiovascular nanomedicine is to reduce the burden of CVD using nanoscale medical products and devices. However, the development of novel multicomponent nano-sized products poses multiple technical, ethical, and regulatory challenges, which often obstruct their road to successful approval and use in clinical practice. This review discusses the rational design of nanoparticles, including safety considerations and regulatory issues, and highlights the steps needed to achieve efficient clinical translation of promising nanomedicinal products for cardiovascular applications.

AB - Cardiovascular diseases (CVD) account for nearly half of all deaths in Europe and almost 30% of global deaths. Despite the improved clinical management, cardiovascular mortality is predicted to rise in the next decades due to the increasing impact of aging, obesity, and diabetes. The goal of emerging cardiovascular nanomedicine is to reduce the burden of CVD using nanoscale medical products and devices. However, the development of novel multicomponent nano-sized products poses multiple technical, ethical, and regulatory challenges, which often obstruct their road to successful approval and use in clinical practice. This review discusses the rational design of nanoparticles, including safety considerations and regulatory issues, and highlights the steps needed to achieve efficient clinical translation of promising nanomedicinal products for cardiovascular applications.

UR - http://www.scopus.com/inward/record.url?scp=85055207494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055207494&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvy219

DO - 10.1093/cvr/cvy219

M3 - Article

C2 - 30165574

AN - SCOPUS:85055207494

VL - 114

SP - 1714

EP - 1727

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 13

ER -